Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 8/20 | 0.47 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.45 |
| ▸ | F10 | P00742 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | FASN | P49327 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 2/20 | 0.41 |
| ▸ | CASP4 | P49662 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL1100995 | 0.95 | DGAT1 (0.44) | DGAT1ROCK2LMNAHSD17B10MAPK1 | |
| SCHEMBL1100061 | 0.92 | FASN (0.45) | DGAT1LMNAHTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL1099248 | 0.91 | ROCK2 (0.43) | DGAT1ROCK2F10LMNAHSD17B10 | |
| SCHEMBL1100754 | 0.90 | PPARG (0.41) | DGAT1MAPK1KDM4EALDH1A1MAPT | |
| SCHEMBL1100196 | 0.89 | GAA (0.46) | DGAT1MAPK1KDM4EALDH1A1MAPT | |
| SCHEMBL1100645 | 0.89 | DGAT1 (0.46) | DGAT1ROCK2LMNAHSD17B10MAPK1 | |
| SCHEMBL1100786 | 0.88 | CNR1 (0.47) | DGAT1KDM4EMEN1KMT2ACYP1A2 | |
| SCHEMBL1100988 | 0.88 | HTT (0.46) | DGAT1F10LMNAKDM4EHTT | |
| SCHEMBL1101063 | 0.87 | ROCK2 (0.47) | DGAT1ROCK2LMNAHSD17B10MAPK1 | |
| SCHEMBL1100170 | 0.87 | KDM4E (0.51) | DGAT1ROCK2LMNAHSD17B10MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8716272-B2 | N-(amino-heteroaryI)-1H-pyrrolopyridine-2-carboxamides derivatives preparation thereof and their use in therapy | SANOFI (FR) | 2014-05-06 | — | — | US | disclosed |
| US-8716273-B2 | N-(amino-heteroaryl)-1H-pyrrolopyridine-2-carboxamides derivatives preparation thereof and their use in therapy | SANOFI (FR) | 2014-05-06 | — | — | US | disclosed |
| EP-2125811-B1 | N-(AMINO-HETEROARYL)-1H-PYRROLOPYRIDINE-2-CARBOXAMIDES DERIVATIVES, PREPARATION THEREOF AND THEIR USE IN THERAPY | SANOFI SA (FR) | 2013-05-29 | — | — | EP | disclosed |
| US-20120142669-A1 | N-(amino-heteroaryl)-1H-pyrrolopyridine-2-carboxamides derivatives preparation thereof and their use in therapy | SANOFI-AVENTIS (FR) | 2012-06-07 | — | — | US | disclosed |
| US-20120142670-A1 | N-(amino-heteroaryl)-1H-pyrrolopyridine-2-carboxamides derivatives preparation thereof and their use in therapy | SANOFI-AVENTIS (FR) | 2012-06-07 | — | — | US | disclosed |
| US-8153650-B2 | N-(amino-heteroaryl)-1H-pyrrolopyridine-2-carboxamides derivatives preparation thereof and their use in therapy | SANOFI-AVENTIS (FR) | 2012-04-10 | — | — | US | disclosed |
| US-20100041634-A1 | N-(amino-heteroaryl)-1H-pyrrolopyridine-2-carboxamides derivatives preparation thereof and their use in therapy | SANOFI-AVENTIS (FR) | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142670-A1 | N-(amino-heteroaryl)-1H-pyrrolopyridine-2-carboxamides derivatives preparation thereof and their use in therapy | ZYX, NQO2, PYCR1 | DGAT1 3777/4885ROCK2 424/4885F10 2817/4885 |
| US-20120142669-A1 | N-(amino-heteroaryl)-1H-pyrrolopyridine-2-carboxamides derivatives preparation thereof and their use in therapy | ZYX, NQO2, PYCR1 | DGAT1 3777/4885ROCK2 424/4885F10 2817/4885 |
| US-20100041634-A1 | N-(amino-heteroaryl)-1H-pyrrolopyridine-2-carboxamides derivatives preparation thereof and their use in therapy | ZYX, NQO2, PYCR1 | DGAT1 3777/4885ROCK2 424/4885F10 2817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.